# QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer

> **NCT07636226** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 120 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** QL1706
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT07636226
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-30
- **Primary completion:** 2028-12-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07636226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07636226, "QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07636226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*